GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT06120556

Completed

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes: an Italian Monocentric Retrospective Study

Lead sponsor

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Assets

Dulaglutide / GLP-1 / incretin class catch-all / Liraglutide / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

130

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥25

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06120556

Org study IDAOUConsorziale

Timeline

Milestones

Study start2023-06-10actual

Primary completion2023-10-31actual

Study completion2023-10-31actual

Study first posted2023-11-07actual

Last update posted2024-01-30actual

Assets

Investigational agents

Dulaglutide GLP-1 / incretin class catch-all Liraglutide Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

All patients who attended the Day Service for diabetes of the Endocrinology Unit of the University Hospital A.O.U. Policlinico di Bari, Puglia, Italy from January 1st 2012 to October 1st 2023 will be consecutively evaluated for inclusion.

Inclusion criteria

•Italian patients with type 2 diabetes

•Onset of diabetes at ≥ 50 years

•Diagnosis of type 2 diabetes ≤ 5 years from enrollment

•BMI ≥ 25 kg/m2

•Patients receiving a GLP-1RA prescription for the first time with at least one follow-up visit at 6-12 months from first prescription

Exclusion criteria

•Autoimmune diabetes, monogenic diabetes, secondary diabetes

•History of diabetic ketoacidosis

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Difference in body weight change from baseline (kg) among SIDD, SIRD, MARD, MOD subtypes

Time frame:Difference in body weight change from baseline (kg) will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

4 endpoints

Primary/protocol endpoint

Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes

Time frame:Difference in HbA1c change from baseline will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Difference in time to failure among SIDD, SIRD, MARD, MOD subtypes

Time frame:Difference in time to failure will be assessed up to the last available visit (up to 36 months)

HbA1c <7.0% achievement

time to event, event

LOINC 4548-4

Secondary/protocol endpoint

Difference in fasting blood glucose change from baseline (mg/dl) among SIDD, SIRD, MARD, MOD subtypes

Time frame:Difference in fasting blood glucose change from baseline (mg/dl) will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Difference in percentage of patients reaching HbA1c below 7% among SIDD, SIRD, MARD, MOD subtypes

Time frame:Difference in percentage of patients reaching HbA1c below 7% will be evaluated at first follow-up visit (occurring 6-12 months from GLP-1RA initiation)

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Clinical characterization of data-driven diabetes subgroups in Mexicans using a reproducible machine learning approach.
BMJ open diabetes research & care2020 Jul (month)PMID32699108doi:10.1136/bmjdrc-2020-001550via CT.gov background
Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data.
The lancet. Diabetes & endocrinology2019 Jun (month)PMID31047901doi:10.1016/S2213-8587(19)30087-7via CT.gov background
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.
The lancet. Diabetes & endocrinology2018 May (month)PMID29503172doi:10.1016/S2213-8587(18)30051-2via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.